---
schema_version: "secwatch.filing_event.v1"
accession: "0001549084-23-000004"
form_type: "8-K/A"
ticker: "CHRN"
cik: "0001549084"
company_name: "EKSO BIONICS HOLDINGS, INC."
filed_at: "2023-02-16T23:59:59+00:00"
generated_at: "2026-06-19T09:22:45.302720+00:00"
event_type: "m_and_a"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Ekso Bionics acquires Parker Hannifin's HMC business for $10M; HMC had $2.2M op loss in FY2022

## Summary
- Acquisition closed Dec 5, 2022; purchase price $10M: $5M cash + $5M subordinated zero-coupon note due Sep 2027.
- HMC FY2022 (Jun 2022) revenue $4.3M, operating loss $2.2M; FY2021 loss $4.0M on $2.7M revenue.
- Pro forma 9mo Sep 2022 combined net loss $14.8M ($1.14 diluted EPS) vs Ekso standalone $11.9M loss.
- Preliminary purchase price allocation: $5.2M intangible assets, $0.7M goodwill, $1.0M property step-ups.
- HMC unaudited 3mo Sep 2022 revenue $390k, operating loss $1.1M.

## SEC filing metadata
- accession: 0001549084-23-000004
- form_type: 8-K/A
- ticker: CHRN
- cik: 0001549084
- company_name: EKSO BIONICS HOLDINGS, INC.
- filed_at: 2023-02-16T23:59:59+00:00
- event_type: m_and_a
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549084/000154908423000004/0001549084-23-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549084/000154908423000004/ekso-20221205.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001549084-23-000004
- JSON: https://secwatch.observer/filing/0001549084-23-000004.json
- Plain text: https://secwatch.observer/filing/0001549084-23-000004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.